Cipla Independent Director Naina Lal Kidwai resigns

Published On 2022-01-27 04:45 GMT   |   Update On 2022-01-27 13:00 GMT

Mumbai: Cipla has recently announced that Ms. Naina Lal Kidwai, Independent Director of the Company has resigned from the position of Independent Director of the Company with effect from close of business hours of 31st March, 2022.

In a letter shared by the Mumbai-based drug firm, the veteran banker noted that she has put in her papers to fulfil several other responsibilities and professional commitments, reports PTI.

"I further confirm that there is no other reason for my resignation as an independent director of the company other than as mentioned in this letter," Kidwai said.

"It has been my privilege to serve as an independent director on the Board of Cipla Ltd and I express my gratitude to the Company and Cipla shareholders for giving me this opportunity. I have witnessed Cipla grow from strength to strength and accomplish many milestones during my long association and take great pride in having been part of this exciting journey. I have no doubt the company will continue to excel under the able leadership of the Board and the talented Management team," 
Kidwai further noted in a letter on BSE.

An MBA from Harvard Business School, Ms Naina Lal Kidwai makes regular appearances in listings of international women in business by Fortune and other publications. A recipient of many awards and honours in India, she was awarded the Padma Shri by the Government of India for her contribution to trade and industry.

Ms Kidwai has authored three books; "Survive or Sink - An Action Agenda for Sanitation, Water, Pollution and Green Finance", "Contemporary Banking in India" and "30 Women in Power: Their Voices, Their Stories."

Ms Kidwai possesses rich experience in the areas of banking and finance. She has been a past president of FICCI; is one of the Government of India's representatives on the BRICs Business Council and the INDO-ASEAN Business Council, the Rajasthan Chief Minister's Economic transformation Advisory Council, the Investment Advisory Committee of the Army Group Insurance Fund; on the Governing Board of Lady Shriram College as well as on the Harvard Business School South Asia Advisory Board.

Read also: Cipla plans to launch Molnupiravir under brand name Cipmolnu

Tags:    
Article Source : with agency inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News